Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LNPEP | Q9UIQ6 | 5/20 | 0.66 |
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.66 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.66 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | CPA1 | P15085 | 1/20 | 0.50 |
| ▸ | CPA2 | P48052 | 1/20 | 0.50 |
| ▸ | CPA4 | Q9UI42 | 1/20 | 0.50 |
| ▸ | ECE1 | P42892 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | TLR2 | O60603 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30565150 | 0.95 | LNPEP (0.60) | LNPEPERAP2ERAP1MMP2CPA1 | |
| SCHEMBL7857079 | 0.95 | LNPEP (0.60) | LNPEPERAP2ERAP1MMP2CPA1 | |
| SCHEMBL1246343 | 0.91 | LNPEP (0.55) | LNPEPERAP2ERAP1MMP2CPA1 | |
| SCHEMBL7857980 | 0.91 | LNPEP (0.55) | LNPEPERAP2ERAP1MMP2CPA1 | |
| SCHEMBL29405428 | 0.89 | LNPEP (0.55) | LNPEPERAP2ERAP1MMP2CPA1 | |
| SCHEMBL29382413 | 0.88 | ERAP2 (0.65) | LNPEPERAP2ERAP1MMP2ECE1 | |
| SCHEMBL28540087 | 0.88 | ERAP2 (0.65) | LNPEPERAP2ERAP1MMP2ECE1 | |
| SCHEMBL29372662 | 0.88 | ERAP2 (0.65) | LNPEPERAP2ERAP1MMP2ECE1 | |
| SCHEMBL1711485 | 0.88 | ERAP2 (0.65) | LNPEPERAP2ERAP1MMP2ECE1 | |
| SCHEMBL170652 | 0.88 | ERAP2 (0.65) | LNPEPERAP2ERAP1MMP2ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025083205-A1 | DRUG COMBINATION COMPRISING ANTI-CD37 ANTIBODY MAYTANSINE CONJUGATE AND BCL2 INHIBITOR OR PI3K INHIBITOR | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2025-04-24 | — | — | WO | disclosed |
| EP-4507734-A1 | LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES | Debiopharm Research & Manufacturing S.A. (CH) | 2025-02-19 | — | — | EP | disclosed |
| WO-2023198884-A1 | LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2023-10-19 | — | — | WO | disclosed |
| US-20210230218-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | MABPLEX INTERNATIONAL, LTD. (CN) | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230218-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | VIP, DNPEP, PREP | LNPEP 10/4885ERAP2 150/4885ERAP1 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.